Lajos Pusztai, MD, DPhil, Member
BCRF Scientific Advisory Committee
Lajos Pusztai received his Doctor of Medicine (MD) degree from the Semmelweis University of Medicine in Budapest, Hungary in 1987. Subsequently he studied at the University of Oxford in England where he received his Doctor of Philosophy degree (D.Phil.) in 1993. He completed his graduate medical training in the USA and has joined the faculty of the University of Texas MD Anderson Cancer Center (MDACC) in 1999, where he is currently Associate Professor of Medicine.
Dr. Pusztai is board certified in Internal Medicine and Medical Oncology, and is a member of several professional societies including the American Society of Clinical Oncology and the American Association for Cancer Research.
He received several international awards including the Soros Scholarship by the George Soros Fundation, New York, the Overseas Research Students Award of the Vice-chancellors and Principals of the Universities of the United Kingdom, a Career Development Award from the US Department of Defense Breast Cancer Research Program and the MD Anderson Aventis Drug Development Award. He has published over 60 peer-reviewed articles on the biology and treatment of breast cancer. He is senior editor of a book on cell proliferation and cancer and also contributed chapters to books such as the Oxford Textbook of Pathology, Computational and Statistical Approaches to Genomics, Molecular Oncology of Breast Cancer, Molecular Pathology in Clinical Practice and the Textbook of Breast Cancer.
Dr Pusztai's current research focuses on the developing pharmacogenomic markers of response to therapy and identifying methods to select the optimal treatment for individual patients. His research also includes identification of novel therapeutic targets. He is also principal investigator of several clinical trials investigating new drugs. He leads the pharmacogenomic project at the Department of Breast Medical Oncology of MDACC. His research is supported by grants from the National Cancer Institute, the US Department of Defense, the Breast Cancer Research Foundation and philanthropic research grants.
Dr Pusztai's current research focuses on developing new drugs for the treatment of breast cancer and identifying methods to select the optimal therapy for individual patients. He is the principal investigator of several clinical trials including two nationwide multicenter studies. He also leads a pharmacogenomic project at the Nelly B. Connally Breast Center of MDACC. His research is supported by the US Department of Defense Breast Cancer Research Program and research grants from MDACC, and he is also recipient of grants and awards from pharmaceutical companies including the Ellence Research Award of Pharmacia Inc.
|
